[go: up one dir, main page]

BR0216002A - imunoconjugados fabricados a partir de anticorpos de gema de ovo e agregado de anticorpos de gema de ovo (igy) para a sua fabricação - Google Patents

imunoconjugados fabricados a partir de anticorpos de gema de ovo e agregado de anticorpos de gema de ovo (igy) para a sua fabricação

Info

Publication number
BR0216002A
BR0216002A BRPI0216002-1A BR0216002A BR0216002A BR 0216002 A BR0216002 A BR 0216002A BR 0216002 A BR0216002 A BR 0216002A BR 0216002 A BR0216002 A BR 0216002A
Authority
BR
Brazil
Prior art keywords
igy
immunoconjugates
antibodies
egg yolk
egg
Prior art date
Application number
BRPI0216002-1A
Other languages
English (en)
Inventor
Wolfgang Bergter
Hartmut Kobilke
Joachim Sroka
Original Assignee
Wolfgang Bergter
Hartmut Kobilke
Joachim Sroka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wolfgang Bergter, Hartmut Kobilke, Joachim Sroka filed Critical Wolfgang Bergter
Publication of BR0216002A publication Critical patent/BR0216002A/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1006—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against or targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1036—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"IMUNOCONJUGADOS FABRICADOS A PARTIR DE ANTICORPOS DE GEMA DE OVO E AGREGADO DE ANTICORPOS DE GEMA DE OVO (IgY) PARA A SUA FABRICAçãO". A presente invenção está relacionada a imunoconjugados oriundos de anticorpos de gema de ovo (IgY) , seu preparo e aplicação em diagnósticos e terapias. Constitui um objeto da presente invenção propor produtos alternativos aos imunoconjugados convencionais para o uso em diagnósticos e terapias. Os imunoconjugados de acordo com a presente invenção são superiores aos anticorpos monoclonais e imunosoros oriundos de mamíferos, assim como aos compostos de IgY oriundos de galinhas convencionais, no que diz respeito ao grau de pureza e direcionamento do antígeno. A fabricação de anticorpos anti-IgY humanos deve ser evitada se possível, e os imunoconjugados deverão ser fabricáveis de maneira economicamente compensadora de uma forma que faça justiça às normas de proteção dos animais e ainda em grandes quantidades. De acordo com a presente invenção, o referido objeto é alcançado por meio de conjugados policlonais de IgY oriundos de anticorpos de gema de ovo intactos (IgY), fragmentos de IgY, construções Fab ou anticorpos humanizados de gema de ovo oriundos de galinhas SPF, preferencialmente de galinhas SPF transgênicas. Os antígenos ou fragmentos de antígeno deverão ser conjugados como um componente imunologicamente eficaz com pelo menos um componente adicional que pode ser um agente sinalizador, um agente ativo ou uma molécula potencializadora.
BRPI0216002-1A 2001-05-15 2002-05-03 imunoconjugados fabricados a partir de anticorpos de gema de ovo e agregado de anticorpos de gema de ovo (igy) para a sua fabricação BR0216002A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10123505A DE10123505A1 (de) 2001-05-15 2001-05-15 Immunkonjugate aus Eidotter-Antikörpern (lgY), deren Konfektionierung und Anwendung in Diagnostik und Therapie
PCT/DE2002/001606 WO2002092136A2 (de) 2001-05-15 2002-05-03 Immunkonjugate aus eidotter-antikörpern (igy), deren konfektionierung und anwendung in diagnostik und therapie

Publications (1)

Publication Number Publication Date
BR0216002A true BR0216002A (pt) 2006-08-29

Family

ID=7684793

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0216002-1A BR0216002A (pt) 2001-05-15 2002-05-03 imunoconjugados fabricados a partir de anticorpos de gema de ovo e agregado de anticorpos de gema de ovo (igy) para a sua fabricação

Country Status (12)

Country Link
US (1) US20040236076A1 (pt)
EP (1) EP1387701B1 (pt)
JP (1) JP2004534752A (pt)
CN (1) CN1509188A (pt)
AT (1) ATE280591T1 (pt)
AU (1) AU2002310996A1 (pt)
BR (1) BR0216002A (pt)
CA (1) CA2447287A1 (pt)
CZ (1) CZ20033409A3 (pt)
DE (2) DE10123505A1 (pt)
RU (1) RU2003136069A (pt)
WO (1) WO2002092136A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148598A (en) * 2002-03-10 2008-04-13 Ely Morag Multifunctional complex for targeting specific phagocytosis of a target agent and a composition comprising it
WO2006096656A2 (en) * 2005-03-07 2006-09-14 Albert Einstein College Of Medicine Of Yeshiva University Methods of applying ionization radiation for therapy of hiv infection
CN1818651B (zh) * 2006-03-13 2010-07-21 东北农业大学 兔抗鹅IgY+IgY(△Fc)(H+L)辣根过氧化物酶标记抗体
WO2008078809A1 (ja) * 2006-12-27 2008-07-03 Japan Science And Technology Agency 鳥類抗体を使用する免疫学的検出方法
WO2012072515A2 (en) * 2010-11-29 2012-06-07 Centre National De La Recherche Scientifique (Cnrs) Lmp1 a diagnostic and prognostic marker for epstein-barr virus (ebv)-associated lymphoma
WO2013170048A1 (en) 2012-05-09 2013-11-14 Advanced Animal Diagnostics, Inc. Rapid detection of analytes in liquid samples
PH12013000059A1 (en) * 2013-02-15 2016-12-12 Yu Gracia Fe Diagnosis and detection of dengue virus infection using chicken egg antibodies
CN104288769B (zh) * 2014-09-17 2017-09-29 陕西建华生物制药有限公司 一种西药外用膏剂及其制备方法
CN108840929A (zh) * 2018-06-20 2018-11-20 深圳市雅臣智能生物工程有限公司 抗人乳头瘤病毒小分子抗体及其组合物以及制备方法和应用
CN110873711B (zh) * 2018-09-04 2022-02-22 华瑞同康生物技术（深圳）有限公司 一种基于全自动化学发光分析仪的血清tk1检测试剂盒
CN111228481A (zh) * 2018-11-28 2020-06-05 万华普曼生物工程有限公司 一种用于治疗幽门螺旋杆菌的鸡IgY双功能抗体
WO2021112174A1 (ja) * 2019-12-03 2021-06-10 国立大学法人東海国立大学機構 光抗菌療法
DK3919073T3 (en) * 2020-06-05 2024-08-19 Schweitzer Biotech Company Ltd Composition for Preventing Infestation and Infection of Sea Lice on Salmon Præparat til forebyggelse af angreb og infektion af havlus på laks
CN117285618A (zh) * 2023-08-25 2023-12-26 黑龙江省安碧捷生物科技有限责任公司 一种抗人乳头瘤病毒IgY抗体的制备方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE6902707U (de) * 1969-04-30 1969-09-25 Gustav Blecher Kg Restwaermeanzeige an speicherheizgeraeten
US4433997A (en) * 1979-04-20 1984-02-28 Stauffer Chemical Co N-Acylsulfonamide herbicidal antidotes
US4495365A (en) * 1980-11-21 1985-01-22 Stauffer Chemical Co. N-Acylsulfonamide herbicidal antidotes
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
CN1085910A (zh) * 1992-10-22 1994-04-27 中国科学院遗传研究所 抗胃癌生物导向药-免疫球蛋白y-植物毒蛋白a
JPH09500271A (ja) * 1993-03-03 1997-01-14 スペクトラル ダイアグノスティックス インコーポレイテッド 卵黄免疫グロブリン（ｉｇｙ）に対するモノクローナル抗体
US5420253A (en) * 1993-09-09 1995-05-30 Willmar Poultry Company, Inc. Method for purifying egg yolk immunoglobulins
US6143559A (en) * 1996-11-18 2000-11-07 Arch Development Corporation Methods for the production of chicken monoclonal antibodies
DE19737453A1 (de) * 1997-08-25 1999-03-04 Biolog Chemisches I Hoppegarte Aviäre, vitelline, gegen pharmakologisch wirksame Substanzen gerichtete Antikörper
JP2000080027A (ja) * 1998-09-02 2000-03-21 Taiyo Kagaku Co Ltd 徐放性製剤

Also Published As

Publication number Publication date
WO2002092136A3 (de) 2003-09-18
DE50201410D1 (de) 2004-12-02
CA2447287A1 (en) 2002-11-21
EP1387701A2 (de) 2004-02-11
CN1509188A (zh) 2004-06-30
ATE280591T1 (de) 2004-11-15
US20040236076A1 (en) 2004-11-25
WO2002092136A2 (de) 2002-11-21
EP1387701B1 (de) 2004-10-27
JP2004534752A (ja) 2004-11-18
DE10123505A1 (de) 2002-11-28
RU2003136069A (ru) 2005-03-27
AU2002310996A1 (en) 2002-11-25
CZ20033409A3 (en) 2004-04-14

Similar Documents

Publication Publication Date Title
BR0216002A (pt) imunoconjugados fabricados a partir de anticorpos de gema de ovo e agregado de anticorpos de gema de ovo (igy) para a sua fabricação
DK1425389T3 (da) Interleukin-15-(IL-15)-specifikke humane antistoffer
RU2558301C2 (ru) Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие
DK1210374T3 (da) Humane, monoklonale antistoffer over for prostataspecifikt membranantigen
UA87804C2 (ru) Моноклональное антитело человека, которое специфически связывается с рецептором инсулиноподобного фактора роста і (igf-ir)
DK1282646T3 (da) Humane monoklonale antistoffer mod dendritiske celler
BRPI0412245A (pt) anticorpos de rg1 e usos destes
ATE540978T1 (de) Humane monoklonale antikörper gegen cd20
WO2003040169A3 (en) Human monoclonal antibodies to dendritic cells
PE20030846A1 (es) Anticuerpos para cd40
AU2003220525A8 (en) Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
BR0210405A (pt) Anticorpo monoclonal humano isolado, hibridoma, transfectoma, animal não humano transgênico, molécula bi-especìfica, composição, imunotoxina, vetor de expressão e métodos para produzir um anticorpo, para inibir o crescimento de uma célula expressando egfr, para induzir a citólise de uma célula expressando egfr, para tratar ou prevenir uma doença mediada por expressão de egfr e para detectar a presença de antìgeno egfr ou uma célula expressando egfr em uma amostra
HRP20150934T1 (hr) Djelovanje na abcb5 u terapiji raka
WO2007026689A1 (ja) ダチョウを用いた抗体、及びその作製方法
US7459158B2 (en) Immunogenic polypeptides for inducing anti-self IgE responses
WO2003081993A3 (en) Transgenic aves producing human polyclonal antibodies
Oho et al. Bovine milk antibodies against cell surface protein antigen PAc-glucosyltransferase fusion protein suppress cell adhesion and alter glucan synthesis of Streptococcus mutans
WO2002059154A3 (en) Neutralizing human monoclonal antibodies against hiv-1, their production and uses
Wongtangprasert et al. Production of a monoclonal antibody against oxytetracycline and its application for oxytetracycline residue detection in shrimp
TWI396695B (zh) 有害動物之控制
Kerekov et al. Suppression of allergen-specific B lymphocytes by chimeric protein-engineered antibodies
Justiz-Vaillant Chicken immunization with Keyhole limpet hemocynin (KLH)-gp120 fragment (254-274) conjugate raises anti-KLH antibodies in egg yolks.
Justiz-Vaillant Chicken immunization with KLH-gp120 fragment (254-274) conjugate.
Shojaeian et al. Heterologous immunization, a way out of the problem of monoclonal antibody production against carcinoma antigen 125

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: A61K 51/10; A61K 47/48; A61K 41/00; A61K 49/00.

Ipc: B82Y 5/00 (2011.01), A61K 41/00 (2006.01), A61K 47

Ipc: B82Y 5/00 (2011.01), A61K 41/00 (2006.01), A61K 47